Optimizing Treatment Strategies for HR+/HER2- Breast Cancer: ESR1 Mutations and Emerging Therapies : Episode 2
Opinion
Video
Evolution of Testing Strategies for ESR1
The key opinion leaders (KOLs) review the current testing methods for detecting ESR1 mutations and explore the existing strategies employed to overcome or delay the development of these mutations and the associated endocrine resistance in patients with HR+/HER2- metastatic breast cancer.
- What are the challenges and limitations of current strategies to overcome or delay the emergence of ESR1 mutations and endocrine resistance?
- Based on the prevalence and impact of ESR1 mutations, what are the key unmet needs in treating this patient population?
Related Videos
Related Content
